Source link : https://newshealth.biz/health-news/pluvicto-vs-arpi-in-prostate-cancer-is-one-better/
TOPLINE: Patients with metastatic castration-resistant prostate cancer who received Lu-177-PSMA-617 (Pluvicto) achieved similar overall survival and had fewer serious adverse events compared to those who switched androgen receptor pathway inhibitors (ARPI) after progressing on a first-line ARPI. However, the authors noted, the overall survival results “were likely confounded by the high rate of crossover” from […]
The post Pluvicto vs ARPI in Prostate Cancer: Is One Better? first appeared on News Health.
—-
Author : News Health
Publish date : 2025-08-14 17:08:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8